Publication:
A Plain Language Summary of the Cepheus Study of Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone for People With Newly Diagnosed Multiple Myeloma Who Are Not Expected to Receive a Stem Cell Transplant

Simple item page
dc.authorwosidBraunstein, Marc/Jwp-8833-2024
dc.authorwosidUsmani, Saad/Hci-4676-2022
dc.authorwosidGrosicki, Sebastian/Aag-2917-2019
dc.authorwosidBeksac, Meral/D-6411-2013
dc.authorwosidMaiolino, Angelo/Aak-1471-2021
dc.authorwosidBahlis, Nizar Jacques/Jzc-9644-2024
dc.contributor.authorUsmani, Saad Z.
dc.contributor.authorFacon, Thierry
dc.contributor.authorHungria, Vania
dc.contributor.authorBahlis, Nizar J.
dc.contributor.authorVenner, Christopher P.
dc.contributor.authorBraunstein, Marc
dc.contributor.authorZweegman, Sonja
dc.date.accessioned2025-12-11T00:48:55Z
dc.date.issued2025
dc.departmentOndokuz Mayıs Üniversitesien_US
dc.department-temp[Usmani, Saad Z.] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA; [Facon, Thierry] Univ Lille, CHU Lille, Serv Malad Sang, Lille, France; [Hungria, Vania] Clin Med Sao Germano, Sao Paulo, Brazil; [Bahlis, Nizar J.] Univ Calgary, Arnie Charbonneau Canc Res Inst, Calgary, AB, Canada; [Venner, Christopher P.] Univ Alberta, Cross Canc Inst, Dept Med Oncol, Edmonton, AB, Canada; [Venner, Christopher P.] Univ British Columbia, BC Canc Vancouver Ctr, Vancouver, BC, Canada; [Braunstein, Marc] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA; [Pour, Ludek] Univ Hosp Brno, Brno, Czech Republic; [Marti, Josep M.] Hosp Univ Mutua Terrassa, Terrassa, Spain; [Basu, Supratik] Royal Wolverhampton NHS Trust, Wolverhampton, England; [Basu, Supratik] Univ Wolverhampton, Natl Inst Hlth & Care Res, CRN West Midlands, Wolverhampton, England; [Cohen, Yael C.] Tel Aviv Sourasky Ichilov Med Ctr, Dept Hematol, Tel Aviv, Israel; [Cohen, Yael C.] Tel Aviv Univ, Fac Med & Hlth Sci, Tel Aviv, Israel; [Matsumoto, Morio] Natl Hosp Org, Shibukawa Med Ctr, Dept Hematol, Gunma, Japan; [Suzuki, Kenshi] Japanese Red Cross Med Ctr, Dept Hematol, Tokyo, Japan; [Hulin, Cyrille] Univ Hosp Pessac, Hop Haut Leveque, Dept Hematol, Pessac, France; [Grosicki, Sebastian] Med Univ Silesia, Sch Publ Hlth, Dept Canc Prevent, Katowice, Poland; [Legiec, Wojciech] St John Dukla Oncol Ctr Lublin Land, Dept Hematol & Bone Marrow Transplantat, Lublin, Poland; [Beksac, Meral] Istinye Univ, Ankara Liv Hosp, Ankara, Turkiye; [Maiolino, Angelo] Inst Amer Ensino Pesquisa & Inovacao, Rio De Janeiro, Brazil; [Maiolino, Angelo] Univ Fed Rio de Janeiro, Rio de Janeiro, Brazil; [Takamatsu, Hiroyuki] Kanazawa Univ, Kanazawa Univ Hosp, Dept Hematol, Kanazawa, Japan; [Perrot, Aurore] Univ Toulouse, CHU Toulouse, IUCT O, UPS,Serv Hematol, Toulouse, France; [Turgut, Mehmet] Ondokuz Mayis Univ, Fac Med, Dept Hematol, Samsun, Turkiye; [Ahmadi, Tahamtan] Genmab US Inc, Plainsboro, NJ USA; [Liu, Weiping] Johnson &Johnson, Shanghai, Peoples R China; [Wang, Jianping; Krevvata, Maria; Carey, Jodi; Carson, Robin] Johnson & Johnson, Spring House, PA USA; [Chastain, Katherine; Lopez-Masi, Lorena] Johnson & Johnson, Raritan, NJ USA; [Vermeulen, Jessica] Johnson & Johnson, Leiden, Netherlands; [Rowe, Melissa] Johnson & Johnson, High Wycombe, England; [Zweegman, Sonja] Vrije Univ Amsterdam, Canc Ctr Amsterdam, Dept Hematol, Amsterdam UMC, Amsterdam, Netherlandsen_US
dc.description.sponsorshipJohnson Johnsonen_US
dc.description.sponsorshipThe CEPHEUS study was sponsored by Johnson & Johnson. We thank the patients who volunteered to participate in this trial, their families, the staff members at the trial sites who cared for them, the members of the independent data and safety monitoring committee (D. Finkelstein, C. O. Landgren, and S. Y. Kristinsson), and representatives of the sponsor who were involved in data collection and analyses.en_US
dc.description.woscitationindexScience Citation Index Expanded
dc.identifier.doi10.1080/14796694.2025.2560134
dc.identifier.endpage3138en_US
dc.identifier.issn1479-6694
dc.identifier.issn1744-8301
dc.identifier.issue24en_US
dc.identifier.pmid41058194
dc.identifier.scopusqualityQ3
dc.identifier.startpage3115en_US
dc.identifier.urihttps://doi.org/10.1080/14796694.2025.2560134
dc.identifier.urihttps://hdl.handle.net/20.500.12712/39490
dc.identifier.volume21en_US
dc.identifier.wosWOS:001590326800001
dc.identifier.wosqualityQ3
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofFuture Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleA Plain Language Summary of the Cepheus Study of Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone for People With Newly Diagnosed Multiple Myeloma Who Are Not Expected to Receive a Stem Cell Transplanten_US
dc.typeArticleen_US
dspace.entity.typePublication

Files

Collections

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu